← All trials
NCT06323824
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- May 31, 2029
- First posted
- Mar 21, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 600
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yale UniversityLead sponsor
- Hennepin HealthcareCollaborator
- Kaiser PermanenteCollaborator
- University of California, San FranciscoCollaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- Alameda Health SystemCollaborator
- The EMMES CorporationCollaborator
- Yale UniversityOfficial
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.